Liz O’Neil

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Certolizumab pegol, a polyethylene glycolated Fc-free Fab’ was efficacious and well tolerated in patients with moderate-to-severe Crohn’s disease in a previously reported randomized, placebo-controlled study. In this paper, we report the effect of certolizumab pegol on health-related quality of life (HRQoL). Patients with moderate-to-severe active Crohn’s(More)
  • 1